




Supplementary Figure 1 XY plots depicting the correlations of cytokines/chemokines in healthy donors, that had a correlation in BCa patients. The significance (p) and Spearman correlation coefficients (r) are presented above their respective graphs. The lines represent the correlation generated for each set of cytokines/chemokines.


Individual distinctive capability of each parameter by QUEST classification





| miRNAs | # of Nodes | C1 disc. | C2 disc. | C3 disc. |
|------------|------------|-------------|-------------|-------------|
| Sum | 3 | 100% | 100% | 100% |
| miR-16 | 2 | no | no | no |
| miR-21 | 3 | 100% | 100% | 86% |
| miR-23α | 3 | 100% | 92% | 43% |
| miR-146α | 3 | 89% | 92% | 56% |
| miR-155 | 3 | 78% | 58% | 100% |
| miR-181α | 2 | no | no | no |

Supplementary Figure 2 Bar charts generated using the QUEST classification trees, when we try to evaluate each variable's distinctive capability separately (sum of ratios and 6 miRNAs). C1 is presented in light blue, C2 in red and C3 in dark blue. The table presents the discrimination percentage for each variable. Discrimination percentage is set as the final value, after we subtract from a perfect score (100%) the percentage of wrongly classified patients for each cluster.

C1 vs non c1




C1 and c2 vs non c1c2




| | AUC | AUC 95%CI | miRSCORE value for max sensitivity - min 1-specificity | Youden Statistic (J) |
|-------------------------|-------|-------------|--|----------------------|
| C1 vs non C1 | 1.000 | 1.000-1.000 | 4.71 | 1.000 |
| C1 and C2 vs non C1, C2 | 1.000 | 1.000-1.000 | 13.75 | 1.000 |

Supplementary Figure 3 ROC curves presenting the discriminatory capabilities of our algorithm miR_{SCORE} . The AUC, Youden’s J and the algorithm value for the best combination of sensitivity-specificity is presented on the table. These algorithm values are used as the Cluster thresholds as presented in the scatter diagram on the right.



Supplementary Figure 4 a) Circulating miRNA values between the 3 clusters (C1 pink, C2 green, C3 red) and Healthy donors, including those stratified by our algorithm, in arbitrary units. The horizontal lines represent the median values of their respective groups.
 b) Circulating cytokine/chemokine values between the 3 clusters (C1 pink, C2 green, C3 red) and Healthy donors, including those stratified by our algorithm. The horizontal lines represent the median values of their respective groups.
 c) Bar charts presenting the percentages of patients within each group that have high (\geq of the median on total patients, red) or low (\leq of the median on total patients, blue) amounts of each circulating cytokine/chemokine we investigated.



Supplementary Figure 5 a) Bar chart depicting the distribution of our established combined immune signatures between the 3 clusters in percentages. Patient tumors with the FCIS are presented in blue, with the UCIS in red and the Rest group is presented in grey.
 b) Bar chart depicting the distribution of 4 HLA alleles (or groups of alleles), A2, A3 superfamily (A3, A11, A31, A33, A68), A24 and DRB1*11 between our 3 clusters in percentages. The percentage of positive patients for each allele is presented in blue, while the negative in red. The p values presented above the charts are calculated using the number of patients and not the percentages.

Supplementary Table 1. Clinicopathological characteristics of patients

| Total Number of Patients | |
|--------------------------|---------|
| n=48 | |
| Median age (years) | Range |
| 56 | 27-78 |
| Tumor size | n (%) |
| T1 | 20 (42) |
| T2 | 25 (52) |
| T3 | 3 (6) |
| LN status | n (%) |
| N0 | 19 (40) |
| N1 | 16 (33) |
| N2 | 11 (23) |
| N3 | 2 (4) |
| AJCC stage (TNM) | n (%) |
| I | 14 (29) |
| IIA | 10 (21) |
| IIB | 11 (23) |
| IIIA | 12 (25) |
| IIIB* | 0 |
| IIIC | 1 (2) |
| Grade | n (%) |
| 1 | 0 |
| 2 | 25 (52) |
| 3 | 23 (48) |
| Hormone receptor | n (%) |
| positive | 40 (83) |
| negative | 8 (17) |
| HER-2/neu | n (%) |
| positive | 15 (31) |
| negative | 33 (69) |
| Ki67 | n (%) |
| <20% | 24 (50) |
| ≥20% | 24 (50) |
| Immune Signature | n (%) |
| FCIS | 13 (27) |
| UCIS | 11 (23) |
| Rest | 24 (50) |

* Stage IIIB patients were not eligible

| <i>Serum</i> | <i>miR-16</i> | <i>miR-21</i> | <i>miR-23α</i> | <i>miR-146α</i> | <i>miR-155</i> | <i>miR-181α</i> |
|-----------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|--------------------------------------|
| <i>miR-16</i> | - | Spearman r= 0.4462 P=0.0027 ** | Spearman r= 0.6663 P<0.0001 *** | Spearman r= 0.7012 P<0.0001 *** | Spearman r= 0.4444 P=0.0032 ** | Spearman r= 0.3726 P=0.0195 * |
| <i>miR-21</i> | Spearman r= 0.4462 P=0.0027 ** | - | Spearman r= 0.7826 P<0.0001 *** | Spearman r= 0.7793 P<0.0001 *** | Spearman r= 0.4894 P=0.0010 ** | Spearman r= 0.3841 P=0.0144 * |
| <i>miR-23α</i> | Spearman r= 0.6663 P<0.0001 *** | Spearman r= 0.7826 P<0.0001 *** | - | Spearman r= 0.8570 P<0.0001 *** | Spearman r= 0.6420 P<0.0001 *** | Spearman r= 0.3835 P=0.0160 * |
| <i>miR-146α</i> | Spearman r= 0.7012 P<0.0001 *** | Spearman r= 0.7793 P<0.0001 *** | Spearman r= 0.8570 P<0.0001 *** | - | Spearman r= 0.4383 P=0.0029 ** | Spearman r= 0.4102 P=0.0086 ** |
| <i>miR-155</i> | Spearman r= 0.4444 P=0.0032 ** | Spearman r= 0.4894 P=0.0010 ** | Spearman r= 0.6420 P<0.0001 *** | Spearman r= 0.4383 P=0.0029 ** | - | Spearman r= 0.1659 P=0.3129 ns |
| <i>miR-181α</i> | Spearman r= 0.3726 P=0.0195 * | Spearman r= 0.3841 P=0.0144 * | Spearman r= 0.3835 P=0.0160 * | Spearman r= 0.4102 P=0.0086 ** | Spearman r= 0.1659 P=0.3129 ns | - |

Supplementary Table 2 Table presenting the correlations between the recorded values of the 6 miRNAs investigated, as measured in the patient sera. The significance (p) and Spearman correlation coefficient (r) are presented for each set of miRNAs

| <i>PBMCs</i> | <i>miR-16</i> | <i>miR-21</i> | <i>miR-23α</i> | <i>miR-146α</i> | <i>miR-155</i> | <i>miR-181α</i> |
|-----------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|
| <i>miR-16</i> | - | Spearman r= 0.7219 P<0.0001 *** | Spearman r= 0.7112 P<0.0001 *** | Spearman r= 0.8087 P<0.0001 *** | Spearman r= 0.5824 P=0.0002 *** | Spearman r= 0.7639 P<0.0001 *** |
| <i>miR-21</i> | Spearman r= 0.7219 P<0.0001 *** | - | Spearman r= 0.8615 P<0.0001 *** | Spearman r= 0.8451 P<0.0001 *** | Spearman r= 0.6655 P<0.0001 *** | Spearman r= 0.6088 P=0.0001 *** |
| <i>miR-23α</i> | Spearman r= 0.7112 P<0.0001 *** | Spearman r= 0.8615 P<0.0001 *** | - | Spearman r= 0.8603 P<0.0001 *** | Spearman r= 0.8212 P<0.0001 *** | Spearman r= 0.6101 P=0.0001 *** |
| <i>miR-146α</i> | Spearman r= 0.8087 P<0.0001 *** | Spearman r= 0.8451 P<0.0001 *** | Spearman r= 0.8603 P<0.0001 *** | - | Spearman r= 0.8599 P<0.0001 *** | Spearman r= 0.7692 P<0.0001 *** |
| <i>miR-155</i> | Spearman r= 0.5824 P=0.0002 *** | Spearman r= 0.6655 P<0.0001 *** | Spearman r= 0.8212 P<0.0001 *** | Spearman r= 0.8599 P<0.0001 *** | - | Spearman r= 0.6339 P<0.0001 *** |
| <i>miR-181α</i> | Spearman r= 0.7639 P<0.0001 *** | Spearman r= 0.6088 P=0.0001 *** | Spearman r= 0.6101 P=0.0001 *** | Spearman r= 0.7692 P<0.0001 *** | Spearman r= 0.6339 P<0.0001 *** | - |

Supplementary Table 3 Table presenting the correlations between the recorded values of the 6 miRNAs investigated, as measured in the patient PBMCs. The significance (p) and Spearman correlation coefficient (r) are presented for each set of miRNAs